Sverige -
svenska -
Läkemedelsverket (Medical Products Agency)
oxaliplatin eugia 5 mg/ml koncentrat till infusionsvätska, lösning
eugia pharma (malta) limited - oxaliplatin - koncentrat till infusionsvätska, lösning - 5 mg/ml - oxaliplatin 5 mg aktiv substans
Sverige -
svenska -
Läkemedelsverket (Medical Products Agency)
fosphenytoin eugia 75 mg/ml (50 mg fe/ml) koncentrat till injektions-/infusionsvätska, lösning
eugia pharma (malta) limited - fosfenytoinnatriumheptahydrat - koncentrat till injektions-/infusionsvätska, lösning - 75 mg/ml (50 mg fe/ml) - fosfenytoinnatriumheptahydrat 98 mg aktiv substans
Sverige -
svenska -
Läkemedelsverket (Medical Products Agency)
sugammadex aspen 100 mg/ml injektionsvätska, lösning
aspen pharma trading limited - sugammadexnatrium - injektionsvätska, lösning - 100 mg/ml - sugammadexnatrium 108,8 mg aktiv substans
Europeiska unionen -
svenska -
EMA (European Medicines Agency)
sugammadex mylan
mylan ireland limited - sugammadex sodium - neuromuskulär blockade - alla andra terapeutiska produkter - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Europeiska unionen -
svenska -
EMA (European Medicines Agency)
sugammadex amomed
aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskulär blockade - alla andra terapeutiska produkter - reversering av neuromuskulär blockad som induceras av rocuronium eller vekuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Europeiska unionen -
svenska -
EMA (European Medicines Agency)
sugammadex adroiq
extrovis eu ltd. - sugammadex sodium - neuromuskulär blockade - alla andra terapeutiska produkter - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Europeiska unionen -
svenska -
EMA (European Medicines Agency)
sugammadex piramal
piramal critical care b.v. - sugammadex sodium - neuromuskulär blockade - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
Europeiska unionen -
svenska -
EMA (European Medicines Agency)
sugammadex fresenius kabi
fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskulär blockade - alla andra terapeutiska produkter - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Sverige -
svenska -
Läkemedelsverket (Medical Products Agency)
sugammadex avansor 100 mg/ml injektionsvätska, lösning
avansor pharma oy - sugammadexnatrium - injektionsvätska, lösning - 100 mg/ml - sugammadexnatrium 108 mg aktiv substans
Sverige -
svenska -
Läkemedelsverket (Medical Products Agency)
sugammadex hameln 100 mg/ml injektionsvätska, lösning
hameln pharma gmbh - sugammadexnatrium - injektionsvätska, lösning - 100 mg/ml - sugammadexnatrium 108 mg aktiv substans